While biosimilars have made significant inroads into the European marketplace, there remain hurdles to the adoption of these lower-cost drugs, especially in lower-income nations; external reference pricing can mean that drugs are priced to wealthier European countries’ financial capabilities, and manufacturers’ launch strategies may bring biosimilars to nations with the greatest market potential first.
While biosimilars have made significant inroads into the European marketplace, there remain hurdles to the adoption of these lower-cost drugs, especially in lower-income nations; external reference pricing can mean that drugs are priced to wealthier European countries’ financial capabilities, and manufacturers’ launch strategies may bring biosimilars to nations with the greatest market potential first.
A paper newly published in Biomed Research International describes factors that limit the increased use of biosimilars in 10 nations where financial constraints are greater than they are elsewhere in Europe.
In 2015, using a survey that collected feedback from 2 policy experts (1 from a public agency and 1 from a private entity) each in Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Lithuania, Poland, Romania, Russia, and Slovakia, researchers sought to understand the policy environment in each country to the eventual uptake of trastuzumab, rituximab, and infliximab biosimilars.
Across the countries, a number of key barriers to patient access to biologic therapy were identified, including:
The respondents said that the key benefit of biosimilars would be increased access to treatment; cost savings and the increased number of treatment options were mentioned only as secondary benefits.
The participants identified the following issues as limiting patient access to biosimilars:
While the authors note that the generalizability of their findings are limited by the small number of policy experts engaged in each country’s survey, they write that their findings indicate a need for more affordable biologic therapies in these less wealthy nations.
“Policy makers have to take a strategic approach to increase societal benefit from biosimilar medicines,” conclude the authors. “Relying on free-market incentives may not be strong enough; hence, active government interventions instead of ‘passive disinvestment’ policies are needed to correct for current access limitations.”
Reference
Inotai A, Csandi M, Petrova G, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts [published online January 10, 2018]. Biomed Res Int. doi: 10.1155/2018/9597362.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.